AI Stock Finder
Loading...
Skip to main content
AI Stock Finder · Updated Oct. 13, 2026

Biomarin Pharmaceutical Inc BMRN Stock Forecast

AI-powered price prediction and analysis for Biomarin Pharmaceutical Inc · Total · absolute moveSwitch to Alpha

Follow
AI 90-Day Forecast ▼ Exact rating locked
7 Days Sign up free to reveal
30 Days Sign up free to reveal
90 Days Sign up free to reveal
AI Confidence n/a Spearman Correlation

See BMRN's Exact Price Target · Create a free account and follow this stock to unlock its full AI forecast — 3 stocks free.

Price

Price Chart

BMRN
Fundamentals

Key Statistics

Market Cap$10.53B
P/B Ratio1.67x
EPS$0.80
Revenue$3.41B
Current Ratio2.39x
D/E Ratio0.85x
Company

About Biomarin Pharmaceutical Inc

Biomarin Pharmaceutical Inc (BMRN) operates within the Life Sciences sector, specifically in the Pharmaceutical Preparations industry.

Life Sciences Pharmaceutical Preparations Nasdaq Large Cap
News

Latest News

Where BMRN sits on the market map

Life Sciences · Pharmaceutical Preparations
Explore the map →
Industry Peers

Pharmaceutical Preparations Peers

Companies sharing the same SEC industry code, one row per issuer, largest first - a classification match, not a curated list of competitors.

CompanyAI SignalMarket CapP/E
BMRN Biomarin Pharmaceutical Inc ▼ $10.53B –
LLY Eli Lilly & Co ▶ $1.10T 41.1x
JNJ Johnson & Johnson ▼ $599.12B 28.5x
ONC Beone Medicines Ltd. ▶ $515.98B –
ABBV Abbvie Inc. ▼ $484.61B 76.8x
MRK Merck & Co., Inc. ▼ $350.29B 110.4x
NVS Novartis Ag ▼ $271.74B –
GSK Gsk Plc ▼ $199.68B –
ABT Abbott Laboratories ▼ $178.73B 28.6x
PFE Pfizer Inc ▶ $161.70B 37.3x
VRTX Vertex Pharmaceuticals Inc / … ▼ $122.98B 27.9x
BMY Bristol Myers Squibb Co ▼ $115.76B 12.5x
REGN Regeneron Pharmaceuticals, Inc. ▼ $77.54B 17.9x
TEVA Teva Pharmaceutical Industries Ltd ▶ $48.07B 68.0x
SNY Sanofi ▼ $47.70B –
RPRX Royalty Pharma Plc ▶ $32.53B 39.9x
ZTS Zoetis Inc. ▼ $30.70B 11.7x
ALNY Alnylam Pharmaceuticals, Inc. ▼ $29.95B –
TAK Takeda Pharmaceutical Co Ltd ▼ $29.46B –
ATHE Alterity Therapeutics Ltd ▶ $26.01B –
ZLAB Zai Lab Ltd ▶ $25.93B –
ROIV Roivant Sciences Ltd. ▶ $24.09B –
UTHR United Therapeutics Corp ▼ $23.31B 17.8x
INSM Insmed Inc ▼ $21.14B –
VTRS Viatris Inc ▶ $19.81B –
ASND Ascendis Pharma A/S ▶ $13.83B –
JAZZ Jazz Pharmaceuticals Plc ▶ $13.66B 14.5x
CORT Corcept Therapeutics Inc ▲ $12.73B –
SMMT Summit Therapeutics Inc. ▶ $12.38B –
BBIO Bridgebio Pharma, Inc. ▲ $12.37B –
KNSA Kiniksa Pharmaceuticals International, Plc ▲ $12.25B –
HCM Hutchmed (China) Ltd ▶ $11.78B –
ELAN Elanco Animal Health Inc ▲ $11.20B –
RDY Dr Reddys Laboratories Ltd ▼ $10.66B –
MDGL Madrigal Pharmaceuticals, Inc. ▶ $10.45B –
PTGX Protagonist Therapeutics, Inc ▲ $8.96B –
CYTK Cytokinetics Inc ▶ $8.57B –
ARWR Arrowhead Pharmaceuticals, Inc. ▲ $8.21B –
AXSM Axsome Therapeutics, Inc. ▼ $8.19B –
SYRE Spyre Therapeutics, Inc. ▲ $7.09B –
IONS Ionis Pharmaceuticals Inc ▶ $7.04B –
PRAX Praxis Precision Medicines, Inc. ▲ $6.79B –
ABVX Abivax S.A. ▼ $6.77B –
ALKS Alkermes Plc. ▶ $6.67B –
LEGN Legend Biotech Corp ▶ $6.61B –
AMRX Amneal Pharmaceuticals, Inc. ▶ $6.25B –
LGND Ligand Pharmaceuticals Inc ▼ $6.05B 30.7x
BLTE Belite Bio, Inc ▲ $5.97B –
RYTM Rhythm Pharmaceuticals, Inc. ▶ $5.96B –
BLRX Biolinerx Ltd. ▶ $5.67B –
MIRM Mirum Pharmaceuticals, Inc. ▲ $5.17B –
ERAS Erasca, Inc. ▲ $5.17B –
PTCT Ptc Therapeutics, Inc. ▶ $5.00B –
TVTX Travere Therapeutics, Inc. ▲ $4.88B –
COGT Cogent Biosciences, Inc. ▲ $4.87B –
AMRN Amarin Corp Plc\Uk ▶ $4.86B –
MANE Veradermics, Inc ▲ $4.86B –
GPCR Structure Therapeutics Inc. ▲ $4.77B –
DNTH Dianthus Therapeutics, Inc. /De/ ▲ $4.34B –
INDV Indivior Pharmaceuticals, Inc. ▶ $4.18B 11.7x
FAQ

FAQ

Is Biomarin Pharmaceutical Inc a good stock to buy?

Our AI analyzes Biomarin Pharmaceutical Inc daily. Check the signal above for the latest recommendation. Always do your own research before investing.

How accurate are Biomarin Pharmaceutical Inc predictions?

A per-ticker accuracy statistic for BMRN is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

How often are forecasts updated?

Biomarin Pharmaceutical Inc forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 13, 2026.

Ready to invest smarter? · Join thousands of investors using AI-powered stock predictions

Sign Up Free

Looking for a deeper analysis of Biomarin Pharmaceutical Inc? View full institutional-grade analysis on Intratio →

AI predictions are based on historical patterns and should not be the sole basis for investment decisions. Past performance does not guarantee future results. Always do your own research.